

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254199 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) *A61K 39/395* (2006.01)
C12Q 1/6886 (2018.01) *A61P 35/00* (2006.01)
A61K 31/7088 (2006.01) *C07K 16/28* (2006.01)
A61K 38/20 (2006.01)

(21) International Application Number:

PCT/US2024/032636

(22) International Filing Date:

05 June 2024 (05.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/471,168 05 June 2023 (05.06.2023) US
63/535,431 30 August 2023 (30.08.2023) US

(71) Applicant: **GMP BIOTECHNOLOGY LIMITED**
[CN/CN]; Unit 2212, 22/F, CC Wu Building, 302-308 Hennessy Road Wanchai, Hong Kong (US).

(72) Inventor; and

(71) Applicant (for US only): **TRIEU, Vuong** [US/US]; 29397 Agoura Road, Suite 107, Agoura Hills, California 91301 (US).


(74) Agent: **ECKMAN, Richard**; 530 Lytton Avenue Suite 200, Palo Alto, California 94301 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-CANCER TGFB2 AGENTS WITH IMMUNOTHERAPEUTICS

FIG. 10



[Download plot as a PDF](#)

Median survival

Low expression cohort (months) High expression cohort (months)
16.57 32.67

(57) Abstract: This invention relates to methods for treating or ameliorating the symptoms of cancer in a human or animal subject with pharmaceutical compositions designed to promote anti-tumor effects. Exemplary synergistic pharmaceutical therapies include compositions having a combination of active agents including agents for inhibiting or suppressing expression of TGF- β 2, immune checkpoint inhibitor agents, and interleukin immunotherapeutic active agents. One or more biomarkers can be used to select subjects who benefit from the method.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*